TABLE 1: Sites of alopecia and other clinical presentations in				
our patients				

our patients			
Area of alopecia	Number of affected patients	% of affected patients	
Scalp			
<ul> <li>Frontotemporal recession</li> </ul>	38	100%	
• Plaques from cicatricial alopecia	4	10%	
Eyebrows	34	89%	
Eyelashes	14	36%	
Body	28	73%	
• Underarms	21	55%	
Cutaneous LP			
• Ungual LP	1	2.6%	
• LP pigmentosus	1	2.6%	
• Papules on forehead	1	2.6%	

## TABLE 2: Systemic and skin comorbidities in our patients

TABLE 2: Systemic and skin comorbidities in our patients			
Comorbidities	Number of affected patients	% of affected patients	
Arterial hypertension	18	47.36%	
Dyslipidemia	14	36.84%	
Depression	14	36.84%	
Thyroid disease	14	36.84%	
Hypothyroidism	11	28.94%	
Hepatopathy	4	10.52%	
Anxiety	3	7.89%	
Diabetes mellitus	2	5.26%	
Cardiopathy	2	5.26%	
Osteoporosis	1	2.63%	
Osteopenia	1	2.63%	
Dermatological Comorbidities			
Non-melanoma skin cancer	3	7.89%	
Vitiligo	2	5.26%	
Systemic lupus erythematosus	1	2.63%	
Psoriasis	1	2.63%	

Despite the limitations of the study, it is possible to confirm the predominance of postmenopausal women among those affected, and we observed some benefit of the treatments in the interruption of the disease's evolution. The frequency of involvement of eyebrows and other body hair should be noted. An association with cutaneous lichen planus in other areas of the body was rare.

The study suggested that the use of hair dye (33 patients; 86.84%) could be included as a risk factor for FFA, and laboratory tests of thyroid function should be requested in patients with FFA.□

## REFERENCES

- Kossard S. Postmenopausal frontal fibrosing alopecia. Scarring alopecia in a 1. pattern distribution. Arch Dermatol. 1994;130:770-4.
- Vañó-Galván S, Molina-Ruiz AM, Serrano-Falcón C, Arias-Santiago S, Rodrigues-2. Barata AR, Garnacho-Saucedo G, et al. Frontal fibrosing alopecia: a multicenter

- review of 355 patients. J Am Acad Dermatol. 2014;70:670-8.
- 3. Tan KT. Messenger AG. Frontal fibrosing alopecia: clinical presentations and prognosis. Br J Dermatol. 2009;160:75-9.
- Moreno-Ramírez D, Camacho Martínez F. Frontal fibrosing alopecia: a survey in 16 patients, J Eur Acad Dermatol Venereol, 2005:19:700-5.
- Faulkner CF, Wilson NJ, Jones SK. Frontal fibrosing alopecia associated with cutaneous lichen planus in a premenopausal woman. Australas J Dermatol. 2002:43:65-7.

# Letícia Dalla Costa Kusano ORCID 0000-0003-3651-7303

Approval of the final version of the manuscript, Conception and planning of the study, Elaboration and writing of the manuscript, Obtaining, analyzing and interpreting the data, Effective participation in research orientation, Intellectual participation in propaedeutic and/or therapeutic conduct of the cases studied, Critical review of the literature, Critical review of the manuscript

Fabiane Andrade Mulinari Brenner

D ORCID

0000-0001-7970-522X

Approval of the final version of the manuscript, Conception and planning of the study, Elaboration and writing of the manuscript, Obtaining, analyzing and interpreting the data, Effective participation in research orientation, Intellectual participation in propaedeutic and/or therapeutic conduct of the cases studied, Critical review of the literature, Critical review of the manuscript

How to cite this article: Kusano LDC, Mulinari-Brenner FA. Frontal fibrosing alopecia: follow-up of a brazilian group. An Bras Dermatol. 2019;94(3):365-7.



The diagnosis of cosmetic contact dermatitis: a study using standard, cosmetic, and hair cosmetic batteries\*

Mariele Bevilaqua<sup>1</sup> Michelle Bortolotto Cichelero<sup>2</sup> Rebeca Kollar Vieira da Silva<sup>2</sup> Renan Rangel Bonamigo<sup>1,3</sup>

DOI: http://dx.doi.org/10.1590/abd1806-4841.20198003

Dear Editor,

Contact dermatitis (CD) is one of the most common diseases seen in dermatological practice. It represents the majority of occu-

Received 18 December 2017.

Accepted 05 August 2018.

- Work conducted at the Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre (RS), Brazil. Financial support: None. Conflict of interest: None.
- Postgraduate program in Pathology, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre (RS), Brazil.
- Medicine Department, Universidade Federal de Ciências da Saúde
- de Porto Alegre, Porto Alegre (RS), Brazil. Service of Dermatology, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre (RS),

Mailing Address: Mariele Bevilagua

E-mail: dramarielebevilaqua@gmail.com

©2019 by Anais Brasileiros de Dermatologia



Letters 367

pational dermatoses and produces a considerable socioeconomic impact, especially in industrialized countries. CD is caused by external agents that trigger inflammatory reactions through multiple mechanisms when they come into contact with the skin. Patch tests are considered the gold-standard complementary exam for the diagnosis of CD.

Data from the literature suggest that 1-5.4% of the population is sensitized to some cosmetic substance, with about 80% of cases occurring among female patients aged between 20 and 60 years.<sup>2</sup> Despite the growing number of cases of CD, Brazilian etiological and epidemiological data are scarce.

The present study - approved by the Ethics Committee of The Federal University of Health Sciences of Porto Alegre (Porto Alegre - RS, Brazil) - evaluated a prospective sample of patients that attended the Dermatology Service at that University aiming to determine the prevalence of allergic CD due to cosmetics and, thus, reveal its etiological profile and associated factors. This cross-sectional study included 28 patients with suspected cosmetic-induced CD (January-October 2016) that agreed with the terms and conditions of the study. Three batteries approved by the Brazilian Society of Dermatology were applied: the Brazilian standard battery, the cosmetic battery, and the hair cosmetic battery (IPI ASACPHARMA®). The results were analyzed according to the criteria of the International Dermatitis Research Group.


The statistical analysis of the data was performed using the SPSS-23 software; *chi-squared tests* with a significance level of 95% (p < 0.05) were used. Females predominated (92.9%) and the median age was 51 years; 43% tested positive for the standard battery, 29% for the cosmetic battery and 11% for the hair cosmetic battery, where nickel (29%), coconut diethanolamine (63%), and decyl glucoside (34%) were, respectively, the most frequent agents in each battery. A total of 89.3% of the tests were considered relevant and the lesions were most frequently located on the head and neck (57.1%). Clinical improvement within 30 days of the removal of allergens was reported by 92.9% of the patients. Angry back syndrome was observed in three patients (10.7%) and patients over 50 years of age were positive in 59.1% of the tests. No significant association was found between history of atopy and testing positive (p <0,610).

Table 1 and graph 1 present the data from the present research and compares them with those found in the literature, thus the following considerations can be made: previous studies found the face to be the region most frequently affected by cosmetic-induced CD, while the present study found a greater frequency in the head and neck. The components of fragrances and preservatives are the most frequent contact cosmetic allergens.<sup>3</sup>

While in the United Kingdom 23% of women and 18,8% of men experienced adverse reactions to a personal care product; in this study, considering all allergens tested, 13 (46%) patients effectively experienced an allergic reaction to some cosmetic component and 11 (39%) had a positive reaction to more than one agent in all three batteries. 4

The most common allergens were nickel, kathon (methylisothiazoline), and cobalt in the standard battery; coconut diethanolamine, amerchol L101, and tosilamide resin in the cosmetic battery; and decylglucoside 5%, lauryl polyglucose, and P-aminophenol in

Table 1: (	General charac	terization of subj	ects
AGE	Up to 50 years: 12 ( 42,9%) 50 years or more: 16 (57,1%)	Extra- Work Activities	Yes: 10 (35,7%) No: 18 (64,35)
SEX	Male: 2 (7,1%) Female: 26 (92,9%)	USE OF INDIVIDUAL PROTECTION EQUIPMENT	Yes: 4 (14,3%) No: 28 (24%)
РНОТОТУРЕ	I: 0 (0%) I: 4 (14,3%) III: 14 (50%) IV: 6 (21,45) V: 3 (10,7%) VI: 1 (3,6%)	HAND HYGIENE	Water and soap: 23 (82,1%) Alcohol: 1 (3,6%) Water: 4 (14%)
RACE	White: 16 (57,1%) Brown: 5 (17,9%) Black: 7 (25%)	EVOLUTION OF DERMA- TITIS	6 months or less: 4 (14%) 6-12 months: 7 (25%) Over 12 months: 17 (60,7%)
SCHOOLING	Primary: 9 (32,1%) Secundary: 10 (35,7%) Higher education: 6 (21,7%) No schooling: 3 (10,7%)	TREATMENT CHOICE	Topical: 5 (17,9%) Systemic: 7 (25%) Both: 6 (21,4%) No treatment: 10 (35,7%)
COMORBIDI- TIES	Present: 24 (85,7%) Absent: 4(14,3%)	LOCATION OF PREVIOUS LESION	Head and neck: 23 (82,1%) Trunk: 9 (32,1%) Limbs: 17 (60,7%)
ALCOHOL COMSUPTION	Yes: 6 (21,5%) No: 22 (78,6%)	LOCATION OF CURRENT LESION	Head and neck: 16 (57,1%) Trunk: 4 (14,3%) Limbs: 15 (61,3%)
SMOKING	Smokers: 2 (7,1%) Non-Smok- ers: 26 (92,9%)	PREVIOUS ATOPY	Personal: 5 (17,9%) Family: 3 (10,7%) Personal and family: 14 (50%) No atopy: 6 (21,4%)



Graph 1: Positive agents (96 hours). Agents that tested positive after 96 hours in the standard battery (A), cosmetic battery (B), and hair cosmetic battery (C)

the hair cosmetic battery. An earlier study showed that nickel presented a higher prevalence of sensitization when isolated than other metals and was the main sensitizer in women.<sup>3</sup>

Kathon, which is used as a cosmetic marker, is considered one of the major clinical causes of allergic dermatitis. A study carried out in São Paulo, Brazil, found that 46% of tests were positive for cosmetics and the main causative agents were butylated hydroxytoluene (BHT) and triethanolamine (causing 19,18% of cases each), followed by ammonium thioglycolate (17,81%), sorbic acid (12,33%), tosylamide (10,95%), and germall (8,22%). <sup>5</sup> In the hair cosmetic battery, we found a lower prevalence of allergies but there are

no studies to establish a comparison.

More studies focusing on the prevalence of CD to cosmetics (including its components) in different regions of Brazil are necessary given their frequent use. Multicentric studies with standardized methodologies and larger patient samples should be encouraged so that the main sensitizing agents and their allergenic potential can be identified and reported.  $\Box$ 

### **ACKNOWLEDGEMENTS**

We would like to thank all patients that participated in the study, the IPI ASACPHARMA company for donating the contact test batteries, and to the UFCSPA Dermatology Service (resident medical colleagues, academics, preceptors and employees).

#### REFERENCES

- Martins LE, Reis VM. Immunopathology of allergic contact dermatitis. An Bras Dermatol. 2011;86:419-33.
- Kumar P, Paulose R. Patch testing suspected allergic contact dermatitis to cosmetics. Dermatol Res Pract. 2014;2014:695387.
- Duarte I, Lazzarini R, Buense R, Pires MC. Contact dermatitis. An Bras Dermatol. 2000:75:529-48.
- González-Munoz P, Conde-Salazar L, Vanó-Galván S. Dermatitis alérgica de contacto a cosméticos. Actas Dermosifiliogr. 2014;105:822-32.
- Silva EA, Bosco MR, Mozer E.. Study of frequency of allergens in cosmetics components in patients with suspected allergic contact dermatitis. An Bras Dermatol. 2012;87:263-8.

AUTHORS'CONTRIBUTIONS				
Mariele Bevilaqua	(D) ORCID	0000-0001-5689-1162		
Conception and planning of the study; Elaboration and writing of the manuscript; Obtaining, analyzing and interpreting the data; Critical review of the literature				
Michelle Bortolotto Cichelero	(D) ORCID	0000-0003-0050-8210		
Elaboration and writing of the manuscript				
Rebeca Kollar Vieira da Silva	D ORCID	0000-0002-6215-2566		
Elaboration and writing of the manuscrip	pt			
Renan Rangel Bonamigo	(D) ORCID	0000-0003-4792-8466		
Conception and planning of the study, Critical review of the manuscript				

How to cite this article: Bevilaqua M, Cichelero MB, Silva RKV, Bonamigo RR. The diagnosis of cosmetic contact dermatitis: a study using standard, cosmetic and hair cosmetic batteries. An Bras Dermatol. 2019;94(3):366-8.